“Moringa is legal to import” is technically true and almost useless as guidance. Whether a shipment clears a port, and whether the finished product can legally sit on a shelf once it arrives, depends on which part of the plant is inside the bag, which preparation it has become, and which market it is entering. This report maps the United States: the outbreak record, the border posture it produced, and the notification pathway that actually gates moringa products. A companion report, Moringa’s EU Regulatory Map, covers Europe and the markets beyond it, where the same questions get structurally different answers.
Four outbreaks, and one lasting import consequence
The largest of them closed on July 22, 2026. FDA and the Centers for Disease Control and Prevention had spent six months on a multistate outbreak of Salmonella Typhimurium and Salmonella Newport infections tied to recalled dietary supplements made with moringa leaf powder imported from India, and folded additional Salmonella Richmond illnesses into the same investigation before closing it. The final tally: 131 illnesses across 38 states, 36 hospitalizations among the 121 people whose records were available, no deaths, and illness onsets running from August 22, 2025 to June 14, 2026, per FDA’s outbreak advisory.
That file had been closed once already, on March 17, 2026 at 97 illnesses across 32 states, then reopened on May 27 after 22 new illnesses surfaced in four states. Recalls over the life of the outbreak covered Live it Up Super Greens powders from Superfoods, Inc., Why Not Natural moringa capsules, and TNVitamins and Doctor’s Pride capsules from Total Nutrition Inc. Of 12 samples pulled from sick people’s homes and from firms in the supply chain, 11 carried an outbreak strain, as Food Safety News reported when the case was declared over.
It was not an isolated event. It was one of four moringa-linked Salmonella outbreaks the two agencies worked between late 2025 and mid-2026.
- An earlier Salmonella Richmond outbreak, 11 illnesses across 7 states with 3 hospitalizations, was declared over on December 4, 2025. Traceback converged on a single lot of organic moringa leaf powder, batch VFD/ORG/MORP/L/24, supplied by Vallon Farmdirect Pvt Ltd of Jodhpur, India, which reached consumers through Food To Live products, Africa Imports, and Member’s Mark Super Greens sold at Sam’s Club.
- An extensively drug-resistant outbreak of Salmonella Newport and Salmonella Kentucky, 10 illnesses across 8 states with 3 hospitalizations and onsets from September 26, 2025 to January 8, 2026, was traced to Rosabella-brand moringa capsules from Ambrosia Brands LLC, sold on eBay, TikTok Shop, Amazon, Shein, Etsy and the brand’s own storefront. FDA never found a root cause but did identify a single supplier behind the affected powder. Both strains resist every first-line and alternative antibiotic normally used to treat Salmonella.
- A fourth outbreak, Salmonella Typhimurium in MOGO-brand moringa capsules distributed by MOGO Moringa LLC of St. Louis, ended on July 17, 2026 with 34 illnesses and 11 hospitalizations. MOGO sourced all of its moringa leaf powder from India. FDA sent investigators to both the ingredient supplier and the manufacturer, and issued observations citing deficiencies at both facilities.
The durable consequence for importers sits in one sentence FDA repeated on two separate advisories: the agency has increased screening of imported moringa powder from India for Salmonella. On the drug-resistant case FDA went further and described the sampling as ongoing prevention work rather than a reaction to any single shipment. Every one of these investigations is now closed. The screening posture they produced is not.
Industry expects the scrutiny to stay
Trade groups read the pattern the same way. Daniel Fabricant of the Natural Products Association told NutraIngredients that the recalls appear to trace to inadequate drying or the absence of validated kill steps in moringa production, and pointed to FDA’s import monitoring lists: now that regulators are seeing the problem recur, he said, they are “certainly going to scrutinize anything that’s labeled moringa.”
FDA’s own dietary supplement office has asked the industry for help defining the fix. Cara Welch, who heads the Office of Dietary Supplement Programs, told a supplement industry meeting in late May that the agency needs “to understand how this happened and what we can do to stop it from happening again,” and the office has issued a call for information on microbial monitoring and mitigation practices for botanicals with similar supply chains.
What has not appeared is a moringa-specific import alert, the mechanism that lets FDA detain shipments without physical examination. Absent that, the pressure reaches importers as sampling at entry and as buyer demands for a validated pathogen-reduction step on leaf powder, rather than supplier attestations and visual inspection.
No blanket GRAS in the US. The notification pathway is the actual gate
There is no single FDA “generally recognized as safe” determination covering moringa as an ingredient category. Moringa oleifera dried leaf powder and moringa seed oil have instead moved through the new dietary ingredient notification pathway under the Federal Food, Drug, and Cosmetic Act. Under that pathway, a company selling a supplement containing an ingredient not marketed in the United States before October 15, 1994 must notify FDA, with the basis for a safety conclusion, at least 75 days before the ingredient enters interstate commerce.
That review has not gone smoothly for moringa. In a May 2018 response letter on public display in FDA’s notification docket, the agency told a UK notifier that its filing for a supplement described as “Moringa dried leaf powder 100% and Moringa seed oil 100%” was incomplete under 21 CFR 190.6. It gave no conditions of use for the seed oil component, no level for each ingredient, no history of use as food, and no supporting references. Because of those gaps, FDA wrote, it “did not evaluate the identity and safety” of the product at all, and the filing “does not provide an adequate basis to conclude” the ingredient would reasonably be expected to be safe as labeled.
Read that precisely. It is a procedural rejection, not a finding that moringa is unsafe. It is also a fair measure of how thin some moringa safety dossiers are. Self-affirmed GRAS determinations for leaf powder used as a conventional food ingredient do exist in industry practice, but a self-affirmed conclusion is not an FDA “no questions” letter, and no moringa substance carries a published response in FDA’s GRAS notice inventory. Stop short of saying moringa “is GRAS” without that qualifier attached.
India’s export stack, and the trade numbers behind it
India accounts for roughly 80 percent of global moringa supply by CBI’s estimate, with the Philippines, Bangladesh, Pakistan, South Africa, Ghana, Mozambique, Kenya, Zambia, Brazil and Peru producing the remainder. To export moringa legally from India, a company registers with the Agricultural and Processed Food Products Export Development Authority for a Registration-cum-Membership Certificate, secures an Import Export Code from the Directorate General of Foreign Trade, and obtains a phytosanitary certificate confirming pest-free status. Exporters also work to FSSAI norms and, in practice, lab testing for pesticide residues, heavy metals and microbiology. Moringa carries no export license or quota restriction under current Indian foreign trade policy, per trade guidance referencing APEDA’s procedures.
Price and volume data underneath that stack is thin and moves. Tridge’s fresh moringa tracker, covering trade under HS code 070999 across more than 130 countries, showed mid-2026 wholesale export prices spanning well under 50 cents per kilogram out of Brazil to a range running past two dollars out of Thailand, with India carrying by far the highest transaction count and the widest quoted spread. The supplier base is shifting at the edges: Malawi’s fresh moringa exports were up about 75 percent year over year and Nicaragua’s about 74 percent, both off very small bases, while Mexico’s shipments slipped.
Market-size figures deserve a health warning. CBI put global demand for moringa ingredients at 5.8 billion dollars in 2018, projected 8.9 percent annual growth through 2025, and estimated the European share of a roughly 10 billion dollar 2025 global market at about 2 billion dollars. Those are projections, not audited customs statistics, and they should be quoted with that caveat attached.
What this means for importers, in practice
There is no single answer to “is moringa approved,” even inside one market. The honest version breaks into parts: which plant part or preparation, and which end use.
- In the US, leaf powder and seed oil in supplements run through new dietary ingredient notification, not a GRAS shortcut, and at least one moringa notification has already been rejected as incomplete.
- Exporters from India need APEDA registration, a DGFT Import Export Code, and phytosanitary certification, with no license or quota barrier standing in the way.
- The four US Salmonella outbreaks are closed, but the response they triggered is not: FDA is screening imported moringa powder from India for Salmonella, and buyers should expect validated kill steps and pathogen testing to be asked about on every lot.
- Europe and Australia draw their lines by species and plant part rather than by outbreak history; the companion report maps those markets.
None of that amounts to a single compliance checklist a buyer can hand to a broker and forget. It amounts to a set of questions that need answering, product form by product form, before the next shipment leaves port.